Liver Stiffness and Serum Alpha-Fetoprotein in Discriminating Small Hepatocellular Carcinoma from Cirrhotic Nodule
- PMID: 27575844
- DOI: 10.1097/RUQ.0000000000000244
Liver Stiffness and Serum Alpha-Fetoprotein in Discriminating Small Hepatocellular Carcinoma from Cirrhotic Nodule
Abstract
Aim: This study aimed to investigate the clinical significance of liver stiffness and serum alpha-fetoprotein (AFP) in differentiating small hepatocellular carcinoma (HCC) from cirrhotic nodule.
Methods: A total of 95 chronic hepatitis B patients who were diagnosed with small HCC (n = 53) or cirrhotic nodule (n = 42) underwent ultrasound elastography point quantification (ElastPQ) examinations on lesion and background liver. Three stiffness parameters, lesion stiffness value (SV), absolute stiffness difference (ASD) of lesion and background liver, stiffness ratio (lesion/background liver) (SR), and serum AFP were retrospectively analyzed. Then, the capabilities of lesion SV, ASD, SR, AFP, and the combination of each individual stiffness parameter with AFP were evaluated in differentiating small HCC from cirrhotic nodule.
Results: Significantly higher lesion SV, ASD, SR, and serum AFP were observed in small HCC compared with cirrhotic nodule patients (all P ≤ 0.0001). By comparing the stiffness parameters on the patients with AFP greater than 20 ng/mL and AFP of 20 ng/mL or smaller, a higher lesion SV and comparable ASD and SR were found in the small HCC patients. The diagnostic accuracy of lesion SV, ASD, SR, and AFP in the discrimination of small HCC and cirrhotic nodule was 0.731, 0.825, 0.820, and 0.789, respectively. Moreover, the improved sensitivity was observed in the combination of liver stiffness with AFP (83%, 100%, and 92% for lesion SV/AFP, ASD/AFP, and SR/AFP, respectively).
Conclusions: This study illustrated that the combination of liver stiffness and serum AFP has considerable clinical value in detecting suspicious small HCC from cirrhotic nodule.
Similar articles
-
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.Panminerva Med. 2017 Dec;59(4):283-289. doi: 10.23736/S0031-0808.17.03353-5. Epub 2017 Jun 23. Panminerva Med. 2017. PMID: 28650134
-
Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.Anticancer Res. 2003 Mar-Apr;23(2C):1747-53. Anticancer Res. 2003. PMID: 12820452
-
Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.PLoS One. 2015 May 21;10(5):e0127518. doi: 10.1371/journal.pone.0127518. eCollection 2015. PLoS One. 2015. PMID: 25996938 Free PMC article.
-
Diagnostic Value of the Combination of Golgi Protein 73 and Alpha-Fetoprotein in Hepatocellular Carcinoma: A Meta-Analysis.PLoS One. 2015 Oct 6;10(10):e0140067. doi: 10.1371/journal.pone.0140067. eCollection 2015. PLoS One. 2015. PMID: 26441340 Free PMC article.
-
Misdiagnosis Based on Neoplastic Markers-Extremely High Alpha-Fetoprotein in Patients with Intrahepatic Cholangiocarcinoma with Literature Review of the Published Cases.Medicina (Kaunas). 2024 Jul 9;60(7):1109. doi: 10.3390/medicina60071109. Medicina (Kaunas). 2024. PMID: 39064538 Free PMC article. Review.
Cited by
-
Liver stiffness assessed by elastography for the evaluation of hepatocellular carcinoma risk in patients with fibrosis: a systematic review and meta-analysis.Radiol Bras. 2025 Jun 2;58:e20240108. doi: 10.1590/0100-3984.2024.0108. eCollection 2025 Jan-Dec. Radiol Bras. 2025. PMID: 40502450 Free PMC article.
-
Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.Cochrane Database Syst Rev. 2021 Apr 15;4(4):CD013346. doi: 10.1002/14651858.CD013346.pub2. Cochrane Database Syst Rev. 2021. PMID: 33855699 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials